GLENMEDE TRUST CO NA - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
GLENMEDE TRUST CO NA ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q4 2020$352,000
-11.8%
1,110
-31.1%
0.00%0.0%
Q3 2020$399,000
+10.5%
1,611
+17.7%
0.00%0.0%
Q2 2020$361,000
+161.6%
1,369
+117.0%
0.00%
+100.0%
Q1 2020$138,0000.0%6310.0%0.00%0.0%
Q4 2019$138,000
+35.3%
631
+20.2%
0.00%
Q3 2019$102,000
-2.9%
525
+4.0%
0.00%
Q2 2019$105,000
+10.5%
505
+5.2%
0.00%
Q1 2019$95,000
+239.3%
480
+140.0%
0.00%
Q4 2018$28,000
-87.3%
200
-81.5%
0.00%
-100.0%
Q3 2018$221,000
-40.6%
1,083
-56.9%
0.00%
-50.0%
Q2 2018$372,000
+14.8%
2,5150.0%0.00%
+100.0%
Q1 2018$324,0000.0%2,5150.0%0.00%0.0%
Q4 2017$324,000
+6.9%
2,5150.0%0.00%0.0%
Q3 2017$303,000
+23.7%
2,515
+3.9%
0.00%0.0%
Q2 2017$245,0000.0%2,4210.0%0.00%0.0%
Q1 2017$245,000
+24.4%
2,421
+26.0%
0.00%0.0%
Q4 2016$197,000
-5.7%
1,9220.0%0.00%0.0%
Q3 2016$209,000
-5.9%
1,922
-2.7%
0.00%0.0%
Q2 2016$222,000
+22.7%
1,975
+2.8%
0.00%0.0%
Q1 2016$181,000
+5.2%
1,9220.0%0.00%0.0%
Q4 2015$172,000
-2.8%
1,9220.0%0.00%0.0%
Q3 2015$177,000
-5.9%
1,9220.0%0.00%0.0%
Q2 2015$188,000
-2.1%
1,9220.0%0.00%0.0%
Q1 2015$192,000
+8.5%
1,9220.0%0.00%0.0%
Q4 2014$177,000
+132.9%
1,922
+60.2%
0.00%
-94.4%
Q2 2009$76,0001,2000.02%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2020
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders